Want a private account? Register your law firm here. You can also submit this campaign inquiry without registering.
Tell us about your law firm and the volume of cases you would like to discuss. PPC SQUARED will email you about next steps and proposed terms.
GABAPENTIN / NEURONTIN — DEMENTIA & COGNITIVE DECLINE INVESTIGATION NEW AND EMERGING PHARMACEUTICAL LITIGATION OPPORTUNITY PPC SQUARED is evaluating marketing and claimant intake opportunities involving long-term gabapentin use and subsequent diagnoses of dementia, Alzheimer's disease, or significant cognitive impairment. Recent medical research has identified a possible association between repeated gabapentin prescriptions and increased rates of cognitive impairment, prompting law firms to investigate potential pharmaceutical product liability claims. Priority claimants include individuals who received six or more gabapentin prescriptions and subsequently developed medically documented dementia or substantial cognitive impairment, particularly before age 65. PPC SQUARED is seeking qualified law firm partners interested in evaluating this emerging litigation and developing targeted claimant acquisition campaigns. This litigation remains investigational. Medical causation and legal liability have not been established, and compensation is not guaranteed.